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BACKGROUND: Cluster of differentiation 70 (CD70) is frequently expressed in renal cell carcinoma (RCC) and has immunomodula-
tory properties. An antibody-drug conjugate targeting CD70, SGN-CD70A, was developed to treat patients with CD70-positive RCC. 
METHODS: The objective of this phase 1, open-label, dose-escalation, multicenter study was to evaluate the safety and tolerability 
of SGN-CD70A and establish its maximum tolerated dose in patients with CD70-positive, metastatic RCC (mRCC). All subtypes of 
RCC were permitted, and no limit was set on the number of prior therapies. Safety assessments consisted of monitoring and record-
ing all adverse events (AEs) and dose-limiting toxicities (DLTs). Treatment response was assessed by radiographic tumor evaluation 
according to the Response Evaluation Criteria for Solid Tumors, version 1.1. A model-based, modified continual-reassessment method 
was used to estimate the probabilities of DLT and response. RESULTS: The maximum tolerated dose was determined to be 30 μg/kg, 
with thrombocytopenia as the DLT. The most common AEs were fatigue (67%), anemia (61%), and thrombocytopenia (56%). Of 18 
enrolled patients, 1 achieved a partial response and 13 achieved stable disease, for a clinical benefit rate of 78%. Limitations of the 
study included the heavily pretreated nature of patients, receipt of a median of 4 prior lines of therapy (range, 1-8 prior lines of therapy), 
and diminishing response potential. CONCLUSIONS: The modest antitumor activity of SGN-CD70A does not support its development 
in mRCC. However, given the high disease control rate in a heavily pretreated population and the modest toxicity profile, CD70 
 remains of interest because of its immunomodulatory properties. Cancer 2019;125:1124-1132. © 2019 American Cancer Society. 
KEYWORDS: antibody-drug conjugate, cluster of differentiation 70 (CD70), kidney cancer, phase 1, renal cell carcinoma, SGN-CD70A.
INTRODUCTION
The management of metastatic renal cell carcinoma (mRCC) has evolved markedly over the course of the past  several 
years. Whereas vascular endothelial growth factor (VEGF)-directed therapies like sunitinib and pazopanib have 
represented a first-line standard for over a decade, these therapies are being quickly supplanted by combinations using 
immunotherapies.1 Specifically, the CheckMate214 trial demonstrated an improvement in overall survival using dual 
checkpoint inhibition with nivolumab and ipilimumab versus sunitinib monotherapy, and this combination was recently 
approved by the US Food and Drug Administration.2 The recently reported Immotion151 trial compared combined 
VEGF and checkpoint inhibition with bevacizumab and atezolizumab versus sunitinib.3 That study also met its initial 
primary endpoint, demonstrating an improvement in progression-free survival (PFS) in a programmed death-ligand 
1 (PD-L1)–positive population.
With doublet therapies being used in the first-line setting (particularly combinations of VEGF and immune check-
point inhibitors), patients who are not cured with these therapies are left with very few options. All other approved 
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therapies for mRCC function by abrogating signaling 
through VEGF or its downstream mediator, the mamma-
lian target of rapamycin (mTOR). Thus, there is a need 
for novel, mechanistically distinct therapies. Cytotoxic 
agents traditionally have not been active for mRCC, 
but an agent that exploits a unique target in this disease, 
 delivering a cytotoxic molecule to mRCC cells, may be 
beneficial. To this end, we examined cluster of differen-
tiation 70 (CD70), a target expressed on tumor cells of 
a wide variety of malignancies, including (but not lim-
ited to) Hodgkin lymphoma, non-Hodgkin lymphoma 
(NHL), RCC,  pancreatic cancer, ovarian cancer, lung 
cancer, and breast cancer.4-6 In a series of 283 patients 
with RCC, we  observed that 72% had increased CD70 
 expression.7 Rates of expression were highest (82%) among 
230  patients who had confirmed clear cell histology.
The exact role of CD70 in RCC pathogenesis is 
unknown; however, there is evidence to suggest that the 
interaction between CD70 and CD27 may allow the 
tumor to escape immune responses through a decrease in 
the effector T-cell/regulatory T-cell ratio.8 In this article, 
we report the results of the first-in-human, phase 1 study 
of the antibody-drug conjugate (ADC) SGN-CD70A 
 directed against the CD70 antigen in patients with 
mRCC. The cytotoxic component of SGN-CD70A is a 
DNA-crosslinking pyrrolobenzodiazepine (PBD) dimer 
drug, which initiates cellular events leading to double 
strand breaks and eventual cellular apoptosis.9
MATERIALS AND METHODS
Patient Eligibility
This phase 1, dose-escalation study (clinicaltrials.gov 
identifier NCT02216890) was designed to evaluate the 
safety and tolerability of SGN-CD70A and to establish 
the maximum tolerated dose (MTD) in patients with 
mRCC and NHL. The current article reports only out-
comes for patients with mRCC, and outcomes for those 
with NHL are presented in a separate report.10 Ten 
centers in the United States recruited patients between 
June 2015 and July 2016 under approval by an institu-
tional review board in accordance with the Declaration 
of Helsinki. All patients provided informed consent 
before they received any study treatment. Eligible 
patients had a pathologically confirmed diagnosis of 
CD70-positive RCC, as determined by central review 
(defined as CD70 expression in at least 50% of the 
sample) with radiographic evidence of metastatic dis-
ease. All histologic subtypes were permitted, and there 
was no limit on prior therapies, with the exception of 
prior anti-CD70–directed therapy. Patients must have 
received at least 2 prior systemic therapies for meta-
static disease, including receptor tyrosine kinase in-
hibitors and/or mTOR inhibitors. Patients were aged 
≥18 years and had an Eastern Cooperative Oncology 
Group performance status 0 or 1, with adequate base-
line renal, hepatic, and bone marrow function, includ-
ing a platelet count ≥100,000/μL
Study Design and Treatment
Patients received SGN-CD70A intravenously on day 1 
of 6-week cycles. The study was initiated with a 3-week 
cycle dosing schedule; however, because prolonged 
thrombocytopenia was observed in patients with NHL, 
the dosing schedule was changed to every 6 weeks to 
allow the bone marrow sufficient time to recover be-
tween doses. Patients were evaluated for response after 
every cycle of treatment for the first 6 cycles, then every 
2 cycles according to the Response Evaluation Criteria 
for Solid Tumors, version 1.1.11 Patients who achieved 
stable disease (SD) or better were eligible to continue 
receiving study treatment until they developed disease 
progression or unacceptable toxicity. Patients who dis-
continued study treatment before disease progression 
were evaluated for response until progression or initia-
tion of new anticancer treatment, whichever occurred 
first.
This study was conducted using a model-based, 
modified continual-reassessment method statistical de-
sign that implemented Bayesian methodology to esti-
mate the probabilities of dose limiting toxicity (DLT) 
and response at each dose level. The dose-toxicity and 
dose-response relations were modeled separately for each 
arm (mRCC or NHL), and the MTD was determined 
separately for each arm. Dose levels for dose escalation 
were 8 (NHL arm starting dose; this dose was not tested 
in patients with RCC), 15, 30, 50, 80, 120, 160, and 
200 μg/kg.
Study Assessments
Nonstandard safety assessments in this study included 
serial electrocardiograms, pulmonary monitoring (pul-
monary function tests), and renal monitoring (routine 
urinalysis with ref lexive microscopy, creatinine clear-
ance, and urine protein:creatinine calculation/24-hour 
local assessments every 3 weeks). Treatment response 
was assessed by radiographic tumor evaluation at pro-
tocol-specified time points. Spiral computed tomog-
raphy scans of the chest, abdomen, and pelvis were 
obtained. Bone scans or f luorodeoxyglucose-positron 
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emission tomography scans had to be obtained to 
follow bone metastasis, if appropriate. Investigator 
 assessments of clinical progression without imaging 
also were allowed.
Pharmacokinetic, Pharmacodynamic, and 
Immunogenicity Assessments
Blood samples for SGN-CD70A pharmacokinetic (PK) 
analysis were collected predose, within 15 minutes after 
the end of infusion; and at t2, 6, and 24 hours and 
3, 7, 14, 21 and 28 days from the start of infusion in 
cycles 1, 2, and 4. Samples were collected only predose, 
within 15 minutes after the end of infusion in other 
cycles, and at the end-of-treatment visit. Blood samples 
for assessing the presence of antitherapeutic antibody 
(ATA) were collected predose on day 1 of the first 5 
 cycles, every fifth cycle thereafter, and at the end- 
of-treatment visit.
Sensitive, qualified assays were used to measure 
concentrations of ADC (SGN-CD70A), total antibody 
(TAb), released-free drug, and PBD in plasma and ATA 
in serum. The assays included enzyme-linked immuno-
sorbent assays and liquid chromatography-tandem mass 
spectrometry assays. The limits of quantification for 
ADC, TAb, and PBD were 2.89 ng/mL, 2.93 ng/mL, 
and 10 pg/mL, respectively. PK parameters were esti-
mated by noncompartmental analysis using Phoenix 
WinNonlin version 6.3 (Certara, Princeton, NJ). Blood 
samples were collected throughout the study to evaluate 
immune responses, as appropriate.
Statistical Analysis
The primary objective of this study was to evaluate the 
safety and tolerability of treatment with SGN-CD70A 
and to identify the MTD of SGN-CD70A in patients 
who had CD70-positive RCC. The model-predicted 
MTD was the highest dose that had an estimated 
DLT rate <30%. The final MTD determination was 
made by the Safety Monitoring Committee based on 
the estimated DLT rate provided by the model and 
the cumulative safety information. Safety endpoints 
included the type, incidence, severity, seriousness, 
and relatedness of adverse events (AEs) and laboratory 
abnormalities. The PK parameters of SGN-CD70A 
ADC, TAb, and PBD (when measurable) were evalu-
ated by noncompartmental analysis and summarized 
by descriptive statistics at each PK sampling time. The 
ATA incidence rate was defined as the proportion of 




In total, 18 patients with mRCC were enrolled and 
treated on the current study. The median patient age was 
64 years (range, 47-74 years). Most patients had the clear 
cell (94%) subtype of RCC at study entry. Additional 
demographic and disease characteristics are presented in 
Table 1. The reasons for discontinuation from study were 
progressive disease (10 patients; 56%), AEs (5 patients; 
28%), and non-AE–related patient decision (3 patients; 
17%).
Safety
AEs that were considered to be DLTs are displayed by 
dose in Table 2. The DLTs encountered for patients with 
RCC in this study were thrombocytopenia events. One 
DLT of grade 3 thrombocytopenia (30-μg/kg cohort) 
reported on study day 16 in cycle 1 recovered to grade 
1 by study day 51. Two other DLTs of grade 4 thrombo-
cytopenia (50-μg/kg cohort) reported on study days 15 
and 22 in cycle 1 recovered to grade 1 by study day 22 
and to grade 2 by study day 29, respectively. In addition 
to 2 DLTs at the 50-μg/kg dose, we observed that pa-
tients experienced difficulty tolerating ≥2 cycles of treat-
ment at this dose because of edema and/or slow platelet 
recovery. Given this observation, the Safety Monitoring 
Committee recommended not assigning any further pa-
tients to treatment at this dose level. The MTD for the 
mRCC population was determined to be 30 μg/kg. Dose 
levels above 50 μg/kg were not tested.
Of the 18 CC patients with RCC, 94% experi-
enced at least 1 treatment-emergent AE (TEAE). TEAEs 
that were observed in >20% of all treated patients are 
listed in Table 3. Treatment-related The TEAEs that 
occurred in >20% of patients were thrombocytopenia 
TABLE 1. Patient Characteristics
Characteristic No. of Patients (%)
Age: Median [range], y 64 [47-74]
Sex: Men 18 (100)




Renal cell carcinoma diagnosis subtype
Clear cell 17 (94)
TFE3 translocation 1 (6)
No. of prior systemic therapies per patient: 
Median [range]
4 [1-8]
Abbreviations: ECOG, Eastern Cooperative Oncology Group; TFE3, tran-
scription factor binding to immunoglobulin heavy constant μ enhancer 3.
aECOG performance status values range from 0 to 5, with higher scores 
indicating greater disability.
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(56%), anemia and fatigue (44% each), and peripheral 
edema (33%). Overall, 15 patients (83%) had at least 1 
TEAE of at least grade 3 severity. Grade 3 TEAEs that 
occurred in >10% of patients were thrombocytopenia 
(22%), anemia (17%), neutropenia (17%), and dehydra-
tion (11%). There were no reports of neutropenic fever.
Across the study, 4 of 18 patients with mRCC 
(22%) had died at the time of study closure (none within 
30 days of the last dose). Five patients (28%) discontin-
ued the treatment because of AEs. Two patients (11%) 
discontinued because of thrombocytopenia (grade 2 and 
4); and the other 3 patients each discontinued because of 
abdominal pain (grade 3), fatigue, and peripheral edema 
(both grade 2). Two patients (11%) had an AE of throm-
bocytopenia, and 1 patient (6%) had an AE of neutro-
penia that led to dose reduction of the investigational 
product.
There were 17 TEAEs of thrombocytopenia. Of 
these, 10 (59%) recovered with median time to resolu-
tion of 3.6 weeks. The median follow-up for unresolved 
thrombocytopenia was 13 weeks. Two patients  experienced 
grade 1 epistaxis during grade 1 or 2 thrombocytopenia 
events. No other bleeding events were reported.
In total, 8 patients (44%) reported treat-
ment-emergent edema. One of these patients in the 
30-μg/kg cohort experienced both generalized edema 
(grade 3; duration, 9 days) and simultaneous gastroin-
testinal edema (grade 2). This patient also experienced 
hypoalbuminemia (grade 2) 12 days earlier that was 
ongoing during edema. No patient had a dose reduc-
tion because of edema.
Efficacy
The best clinical response observed at all dose levels is 
displayed in Table 4. One patient in the 50-μg/kg  cohort 
achieved a partial response (PR) (6%), with a time to 
first response of 18.4 weeks and a response duration 
of ≥7.3 weeks (Fig. 1). Most patients (13 of 18; 72%) 
had SD, yielding an overall disease control rate of 78% 
(95% confidence interval, 52.4%-93.6%). Tumor size 
TABLE 2. Dose-Limiting Toxicities in Patients With Metastatic Renal Cell carcinoma
DLT
SGN-CD70A Dose
Total, N = 1815 mcg/kg, n = 3 30 mcg/kg, n = 7 50 mcg/kg, n = 8
Thrombocytopenia/platelet count decrease: 
No. of patients (%)
0 (0) 1 (14) 2 (25) 3 (17)
DLT rates and probability
DLT rate: Mean ± SD, % 10.2 ± 0.064 14.3 ± 0.072 23.0 ± 0.114 —
Model-based probability of DLT rate <30% .988 .968 .748 —
Abbreviations: DLT, dose-limiting toxicity; SD, standard deviation.
TABLE 3. Summary of Frequent (≥20%) Adverse Events in Patients With Metastatic Renal Cell Carcinoma
Adverse Event
No. of Patients (%)
SGN-CD70A Dose
Total, N = 1815 mcg/kg, n = 3 30 mcg/kg, n = 7 50 mcg/kg, n = 8
Fatigue 2 (67) 2 (29) 8 (100) 12 (67)
Anemia 2 (67) 4 (57) 5 (63) 11 (61)
Thrombocytopenia 1 (33) 3 (43) 6 (75) 10 (56)
Arthralgia 2 (67) 4 (57) 1 (13) 7 (39)
Peripheral edema 1 (33) 2 (29) 4 (50) 7 (39)
Dyspnea 1 (33) 1 (14) 4 (50) 6 (33)
Nausea 0 (0) 1 (14) 4 (50) 5 (28)
Abdominal pain 0 (0) 1 (14) 3 (38) 4 (22)
Increased blood alkaline 
phosphatase
0 (0) 1 (14) 3 (38) 4 (22)
Dehydration 0 (0) 1 (14) 3 (38) 4 (22)
Hypoalbuminemia 0 (0) 1 (14) 3 (38) 4 (22)
Pain in extremity 0 (0) 2 (29) 2 (25) 4 (22)
Pleural effusion 1 (33) 2 (29) 1 (13) 4 (22)
Pyrexia 1 (33) 0 (0) 3 (38) 4 (22)
Vomiting 0 (0) 2 (29) 2 (25) 4 (22)
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post-treatment is illustrated in Figure 2. It is noteworthy 
that 2 patients (1 with PR and 1 with SD) in the 50-μg/kg 
cohort had ongoing tumor reductions more than 6 weeks 
after the end of treatment (each patient had received 
2 doses). Both patients experienced grade 2 thrombocy-
topenia, which was persistent in 1 patient. The estimated 
Figure 1. A partial response to SGN-CD70A is illustrated in a patient who had metastatic renal cell carcinoma. (A) Pretreatment 
and (B) post-treatment images indicate tumor reductions in pulmonary (Top) and gluteal (Bottom) lesions.
TABLE 4. Summary of Responses in Patients With Metastatic Renal Cell Carcinoma
Response
No. of Patients (%)
SGN-CD70A Dose
Total, N = 1815 mcg/kg, n = 3 30 mcg/kg, n = 7 50 mcg/kg, n = 8
Best clinical responsea
PR 0 (0) 0 (0) 1 (13) 1 (6)
SD 3 (100) 4 (57) 6 (75) 13 (72)
Progression 0 (0) 3 (43) 1 (13) 4 (22)
PD 0 (0) 2 (29) 1 (13) 3 (17)
CPb 0 (0) 1 (14) 0 (0) 1 (6)
ORR: CR + PR 0 (0) 0 (0) 1 (13) 1 (6)
95% CI for ORRc 0.0-70.8 0.0-41.0 0.3-52.7 0.1-27.3
DCR: CR + PR + SD 3 (100) 4 (57) 7 (88) 14 (78)
95% CI for DCRc 29.2-100.0 18.4-90.1 47.3-99.7 52.4-93.6
Abbreviations: CI, confidence interval; CP, clinical progression; CR, complete response, DCR, disease control rate; ORR, objective response rate.
aClinical response was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
bPatients who had both PD and CP were counted as PD. Patients who could not be assessed or were assessed with better than PD according to RECIST, but 
who had an investigator claim of CP at the same visit, were counted as CP.
cTwo-sided 95% exact CIs were calculated using the Clopper-Pearson method.12
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median PFS was 3.5 months (95% confidence interval, 
2.1-6.3 months) (Fig. 3). Four patients are known to have 
died, and 14 were still alive at the last follow-up, includ-
ing the patient who had a PR. The follow-up for those 
who remained alive at the last follow-up ranged from 
≥1.4 to ≥9.7 months. Two patients who died were known 
to have survived for 17.6 and 14.1 months with a best 
 response of SD. Prior immunotherapy with programmed 
death 1 (PD-1)/PD-L1 inhibitors was received by 
4 patients (22.2%); however, the patient who attained a 
PR was not among them.
Pharmacokinetics and Immunogenicity
PK parameters are summarized in Table 5. After 
patients received intravenous SGN-CD70A, plasma ADC 
concentrations appeared to decrease biexponentially, 
with a mean terminal half-life (t1/2) between 4 and 5 days 
across the 15-μg/kg to 50-μg/kg every-6-weeks dose levels 
(Fig. 4). After the first dose, the plasma ADC end-of- 
infusion concentration (Ceoi) and exposure (area under the 
curve [AUC] from 0 to infinity) were approximately dose- 
proportional. There was minimum accumulation across 
cycles, because the geometric mean of accumulation ratio 
was approximately 1.0 for AUC0-42 days.
Plasma TAb concentration-time profiles for SGN-
CD70A were similar to those of the ADC, but the exposure 
of TAb was generally slightly higher. Plasma levels of the 
unconjugated cytotoxic agent PBD were below the lower 
limit of quantification (10 pg/mL) in all samples obtained 
from all patients at dose levels of from 15 to 50 μg/kg, 
Figure 3. Median progression-free survival is illustrated in 
patients with metastatic renal cell carcinoma who received 
SGN-CD70A (N = 18). CI indicates confidence interval; PD, 
progressive disease.
18 (0) 13 (4) 6 (11) 4 (12) 2 (14) 0 (15)
N at Risk (Events)

































TABLE 5. First-Dose Pharmacokinetic Parameters for SGN-CD70A Antibody-Drug Conjugate and Total 
Antibody
PK Parameter
First-Dose PK Parameters: Geometric Mean (% Coefficient of Variation)
15 mcg/kg, n = 3 30 mcg/kg, n = 7 50 mcg/kg, n = 8
SGN-CD70A ADC
AUC0-42d, ng*d/mL 913.32 (46) 1545.99 (38) 2442.88 (44)
AUCinf, ng*d/mL 916.40 (46) 1549.15 (38) 2454.57 (43)
Ceoi, ng/mL 294.00 (—) 720.22 (51) 1166.79 (38)
t1/2, d 5.49 (6) 4.89 (21) 4.89 (34)
Vss, mL 7913.65 (44) 6796.59 (29) 8161.57 (28)
CL, mL/d 1473.16 (64) 1592.13 (29) 1790.55 (28)
SGN-CD70A TAb
AUC0-42d, ng*d/mL 1190.78 (53) 2048.46 (47) 2642.13 (52)
Ceoi, ng/mL 294.00 (—) 627.13 (25) 1064.67 (33)
Abbreviations: ADC, antibody-drug conjugate; AUC0-42d, area under the curve from 0 to 42 days; AUCinf, area under the curve from 0 to infinity; Ceoi, concentra-
tion at the end of infusion; CL, clearance; t1/2, terminal half-life; PK, pharmacokinetic; Tab, total antibody; Vss, volume of distribution at steady state.
Figure 2. Tumor size is illustrated over time (N = 18). 
Diamonds indicate response assessments that occurred 
after the last dose. CP indicates clinical progression; PD, 
progressive disease; PR, partial response; SD, stable disease.
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except for a single sample (26.6 pg/mL) from 1 patient 2 
hours after a 30-μg/kg SGN-CD70A dose.
Among the patients who received treatment 
(N = 18), ATA data were available for 15 (83%). None of 
these patients tested positive for anti-SGN-CD70A anti-
body at any visit during the study.
DISCUSSION
The current study identified modest single-agent activ-
ity with SGN-CD70A in patients with mRCC: 1  patient 
achieved a PR, and 13 patients achieved SD among 
18 enrolled. Although minimal response was observed 
in this data set, most patients derived a clinical  benefit. 
Therefore, CD70 remains an interesting target for 
 potential future RCC therapies.
The most common drug-related TEAEs of SGN-
CD70A were thrombocytopenia, fatigue, anemia, and 
peripheral edema. Several biomarkers were examined to 
determine the cause for severity and duration of observed 
thrombocytopenia in the absence of other significant 
myelosuppression, including evaluation of immunoglob-
ulin G antibody and thrombopoietin levels. None of 
these analyses correlated with the occurrence or degree 
of thrombocytopenia (unpublished data). In addition, 
CD70 is not known to be expressed on megakaryocytes 
or their precursors. Whereas fatigue and anemia are 
common cancer-related symptoms, the rate of edema- 
related events was unexpected. The mechanism for 
edema is  unclear. Mechanistic studies in immune throm-
bocytopenia suggest that CD70 may be involved in plate-
let destruction.13 Thus, an anti-CD70–directed therapy 
would not be anticipated to cause thrombocytopenia. 
Therefore, it is possible that the heavily pretreated nature 
of the  patient population may account for the rates of 
thrombocytopenia (ie, it could be disease-related).
Modest activity was observed with SGN-CD70A 
monotherapy. Multiple factors may account for this, but 
the most important may be the extensive pretreatment 
of patients in the current study. Patients had received a 
median of 4 lines of prior therapy, ranging from 1 to 8 
prior treatments. A clear diminution of antitumor activ-
ity is observed across lines of therapy for mRCC. In the 
front-line setting, PFS for most VEGF-directed therapies 
(eg, sunitinib or pazopanib) ranges from 9 to 11 months.14,15 
PFS with preferred agents in the second-line setting var-
ies but may be as high as 7 to 8 months with agents like 
cabozantinib.16 Trials in the third-line setting have yielded 
much more limited results—the phase 3  experience com-
paring dovitinib (a nonselective fibroblast growth factor 
receptor inhibitor) versus sorafenib yielded a PFS in the 
3-month to 4-month range.17 In the current study, SGN-
CD70A was applied essentially as fifth-line therapy.
Another important element to consider in this 
biomarker-based study is the potential effect of tumor 
heterogeneity. Our prior data indicated that upward 
of 70% of patients with mRCC had CD70 expression. 
However, it is unknown whether there is discordance in 
CD70 expression between primary and metastatic sites 
or whether CD70 expression changes during the course 
of therapy. Multiple studies have suggested substantial 
genomic heterogeneity between primary and  metastatic 
sites in RCC, with few ubiquitous mutations and multi-
ple “private” mutations (eg, mutations exclusive to single 
sites of disease).18,19
A potential future anti-CD70 therapy may be 
of interest either as monotherapy or in combination 
with emerging immunotherapeutic agents. There is 
evidence that CD70 may play a role in T-cell traffick-
ing and myeloid-derived suppressor cell recruitment.8 
Currently, the only front-line immunotherapy combi-
nation with demonstrated benefit in a phase 3 trial in 
mRCC is nivolumab plus ipilimumab, a PD-1 inhibi-
tor and a cytotoxic T-lymphocyte antigen 4 (CTLA-4) 
inhibitor, respectively.2 However, trials combining 
PD-1/PD-L1 inhibitors with novel immunotherapeutic 
strategies (eg, CD-122–based agonist NKTR-214) are 
moving forward.20 These studies demonstrate high 
response rates, suggesting synergy with the  approach 
of dual immune targeting, and they also appear to 
offer less toxicity than the combination of PD-1/
PD-L1 and CTLA-4 blockade.
Figure 4. The first-dose antibody-drug conjugate mean 
concentration-time profile is illustrated for patients who 
received SGN-CD70
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In summary, there are certain factors (eg,  extent of 
prior therapy, tumor heterogeneity) that could  account 
for the modest clinical activity observed with SGN-
CD70A. Given the immunomodulatory properties of 
the compound, CD70 remains an interesting target for 
potential future RCC therapies in combination with 
emerging therapeutic agents.
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